Effect of sodium-glucose cotransporter-2 inhibitors on skeletal muscle
European Journal of Internal Medicine · 2025-11 · 141 · 106420
DOI: 10.1016/j.ejim.2025.07.016 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Internal Medicine, 2025-11. Verfasst von Claudia Stöllberger und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institut Gesünder Leben, Vienna, Austria. Electronic address: claudia.stoellberger@chello.at. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Muscle, Skeletal, Sarcopenia. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 84 Literaturangaben.
Abstract (Originalsprache)
Empagliflozin and dapagliflozin, frequently prescribed Sodium-Glucose- Cotransporter2-inhibitors (SGLT2i), are now also recommended for nondiabetic patients with heart failure (HF). Since concerns exist about myopathy and sarcopenia as adverse effects of SGLT2i, the review summarizes effects of dapagliflozin and empagliflozin on skeletal muscle. PubMed was searched for "SGLT2" OR "SGLT2 inhibitors" OR "SGLT2i" OR "dapagliflozin" OR "empagliflozin" AND "myopathy" OR "sarcopenia" OR "skeletal muscle" OR "muscle loss" OR "muscle weakness" OR "muscle wasting" OR "myotoxicity" OR "muscle atrophy" OR "rhabdomyolysis". Excluded were reviews, editorials, study protocols, letters to the editor, in vitro and in vivo studies. Myopathy/rhabdomyolysis were reported in 5 patients, 3 with concomitant statins, whereas 3 clinical/pharmacovigilance studies found no increased myopathy/rhabdomyolysis-risk with a SGLT2i-statin-combination. SGLT2i-associated sarcopenia was studied in small cohorts ( 6 months in only 32 % of the studies, HF-patients were included in 26 %. Controversial data are reported for muscle-mass, which decreased in 15 and remained unchanged in 6 studies. Physical-performance-tests remained unchanged under SGLT2i. Muscle-biopsies found SGLT2i-assosciated metabolic changes and myofiber-atrophy, but no correlation with functional tests were reported. Exercise or dietary measures did not influence SGLT2i-associated loss of muscle-mass. Two pharmacovigilance studies identified SGLT2i as risk factors for sarcopenia. Data on SGLT2i-associated effects on skeletal muscle are limited and controversial. There is an urgent need for research, especially in nondiabetic, non-Japanese and HF-patients. Since sarcopenia develops over time, observation periods of >12 months are necessary.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institut Gesünder Leben, Vienna, Austria. Electronic address: claudia.stoellberger@chello.at.
- Neurology & Neurophysiology Center, Vienna, Austria.
- Sana Kliniken Lübeck, Lübeck, Germany.
Zitieren
APA
Stöllberger, C., Finsterer, J., & Schneider, B. (2025). Effect of sodium-glucose cotransporter-2 inhibitors on skeletal muscle. European Journal of Internal Medicine, 141, 106420. https://doi.org/10.1016/j.ejim.2025.07.016
Vancouver
Stöllberger C, Finsterer J, Schneider B. Effect of sodium-glucose cotransporter-2 inhibitors on skeletal muscle. European Journal of Internal Medicine. 2025;141:106420. doi:10.1016/j.ejim.2025.07.016
BibTeX
@article{Stllberger2025,
author = {Stöllberger, Claudia and Finsterer, Josef and Schneider, Birke},
title = {Effect of sodium-glucose cotransporter-2 inhibitors on skeletal muscle},
journal = {European Journal of Internal Medicine},
year = {2025},
volume = {141},
pages = {106420},
doi = {10.1016/j.ejim.2025.07.016}
}
EUVIMED